Loading…

Omnicell, Inc.OMCLCompetitor analysis, valuation and peers

United States · USD·Information Technology›Information Technology Services

Makes automated medication dispensing cabinets and pharmacy workflow software used by hospitals and pharmacies.

Momentum weak 39
Mkt cap
$1.59B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$22.6M
20-day average traded
Fwd P/E
18.5×
forward earnings
ROIC−WACC
-4.7 pp
WACC 9.1%
Hurdle
+5 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · USD$34.66
1D+1.9%
1W-2.6%
1M-5.0%
3M-2.4%
6M-22.5%
YTD-23.5%
1Y+1.4%
ATR %4.3%
Beta1.06
52w lowhigh37.0% off high

What Omnicell does

Makes automated medication dispensing cabinets and pharmacy workflow software used by hospitals and pharmacies.

Sells cabinets and robotic dispensing systems to hospitals and pharmacies, then earns recurring revenue from software subscriptions and service contracts on the installed base, a mix it has been trying to grow.

Products and services

  • Automated dispensing cabinets
  • Pharmacy workflow software
  • Medication adherence packaging

Customers

  • Hospitals
  • Retail/specialty pharmacies
  • Long-term care facilities

Where it sits in the supply chain

  • Healthcare technology
  • Medication management automation
  • Hospital and pharmacy customers

What could go right

  • Hospital medication-safety technology adoption
  • Central-fill pharmacy automation growth

What could go wrong

  • Hospital capex cyclicality
  • Competition from larger med-tech (BD)

Moat: narrow (installed base, switching costs, regulatory licence). Hardware/software embedded in hospital medication workflows is costly and risky for hospitals to replace.

Headquarters: Cranberry Township, Pennsylvania, United States · Founded: 1992 · Employees: 3,580

Named competitors

  • BD (Pyxis) BDX
  • Swisslog Healthcare private or unlisted
  • ScriptPro private or unlisted
  • Parata Systems private or unlisted

Omnicell at a glance

Size Omnicell (OMCL) is a United States Information Technology company (Information Technology Services) with a market value of $1.59B, the 1927th largest of 3,085 United States companies the cockpit tracks. Shares closed at $34.66 on 18 Nov 2026.

Performance Over six months the shares fell 22.5%, against -6.9% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 20 in its peer set.

Growth Revenue grew 5.6% over the last twelve months (peer median +5.3%); the operating margin is 5.3% (peer median 7.7%).

Valuation It trades at 18.5× forward earnings against a peer median of 23.2× (5th cheapest of 16).

Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.7 points below its cost of capital (9.1% WACC).

Backlog Backlog (remaining performance obligations) was $375M at 30 Sep 2026, down 1% on a year earlier — 0.3 years of trailing revenue. Backlog detail →

Credit Omnicell has 1 bond outstanding ($172M).

Short interest Short interest is 8.2% of the free float (30 Oct 2026).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026Peer median 93OMCL 79
Six months, rebased to 100: Omnicell against the median of its 20 peers (local-currency closes).

Omnicell financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.24B$1.18B$1.11B$1.15B$1.30B
Revenue growth—+7%-3%-11%—
Gross profit$561M$508M$476M$500M$597M
EBITDA$162M$98.3M$95.2M$76.2M$120M
Net income$44.7M$2.05M$12.5M-$20.4M$5.65M
Free cash flow$143M$84.5M$151M$140M$30.2M
Capital expenditure$55.9M$60.4M$52.8M$55.0M$60.7M
Total debt$201M$204M$383M$614M$617M

Quarterly statements and history in the cockpit →

Omnicell competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%0%+20%002268KNOSZENTECBBOX002987PDFS6008504373VOYGDTL3697FORTY300469300377600718MGRTGLOBCNXC9449OMCL6-month return →1-month return →
Up and to the right = strong over both horizons. Omnicell is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%0×20×40×60×002268KNOSESDSZENTECBBOX002987PDFS6008504373DTL3697600718GLOBCNXC9449OMCLRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Omnicell is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%KNOSESDSZENTEC0029876008504373DTL3697FORTY600718GLOBCNXCOMCLGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Omnicell is the large dot.

Omnicell competitors and peer comparison

Head to head with its named competitors (OMCL vs BDX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Omnicell OMCL$1.59B-22%+6%5%18.5×10.7%
Becton Dickinson BDX$58.9B+48%-7%16%16.3×-1.6%

How Omnicell compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Omnicell against its 20 peers (data as of 18 Nov 2026)
MeasureOMCLPeer medianRank in peer set
1-month return-5.0%-4.2%11th highest of 21
6-month return-22.5%-6.9%4th lowest of 20
Distance from 52-week high-37.0%-35.2%9th lowest of 21
Revenue growth (TTM)+5.6%+5.3%11th highest of 21
Operating margin5.3%7.7%8th lowest of 21
Forward P/E18.5×23.2×5th cheapest of 16
Growth the price implies (Req g, 7 yrs)10.7%14.1%6th least demanding of 13
Growth delivered (Del g)+5.8%+15.9%3rd lowest of 13
Hurdle (Req g minus delivered)+4.9 pp-6.0 pp3rd most demanding of 13
ROIC minus cost of capital-4.7 pp-4.4 pp9th highest of 17
EV / EBITDA9.0×21.8×3rd cheapest of 11
Net debt / EBITDA-0.8×-0.9×6th most indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Omnicell OMCLUnited States$1.59B-22%+6%5%18.5×10.7%+5.8%
CETC Cyberspace Security Technology 002268.SZChina$1.59B-15%-3%1%40.5×n/an/a
Kainos KNOS.LUnited Kingdom$1.63B+21%+32%11%19.8×17.0%+12.9%
ESDS Software Solution ESDS.NSIndia$1.53Bn/a+31%36%71.0×25.2%+22.4%
Zen Technologies ZENTEC.NSIndia$1.67B+10%+4%31%45.0×53.2%+66.0%
Black Box BBOX.NSIndia$1.67B-7%+16%7%50.6×n/an/a
Northking Information Technology 002987.SZChina$1.52B-22%+1%6%27.7×14.5%+16.1%
PDF Solutions PDFSUnited States$1.52B-20%+22%9%23.2×n/an/a
CETC Digital Technology 600850.SSChina$1.50B-19%-1%2%16.0×17.8%+5.8%
Simplex Holdings,Inc 4373.TJapan$1.72B+21%+20%23%20.5×13.6%+16.3%
Voyager Technologies VOYGUnited States$1.47B-41%+42%-82%n/an/an/a
Data#3 DTL.AXAustralia$1.46B+68%+6%8%31.2×26.6%-14.2%
Shift 3697.TJapan$1.74B+63%+24%11%18.8×-1.4%+28.6%
Formula Systems (1985) Ltd. Sponsored ADR FORTYUnited States$1.76B-13%+1%8%n/a-3.0%+6.3%
Transportation Telecommunication and Information Development Inc. Ltd. Zhejiang 300469.SZChina$1.43B-29%-15%-102%n/an/an/a
Shenzhen YSSTech Information Technology 300377.SZChina$1.42B-27%+14%-3%n/an/an/a
Neusoft 600718.SSChina$1.40B-7%-5%-5%34.4×-7.3%+9.7%
Mega Fortune MGRTUnited States$1.84B-2%-8%-37%n/an/an/a
Globant GLOBUnited States$1.84B+2%-1%10%7.2×-2.4%+24.7%
Concentrix CNXCUnited States$1.85B+22%+3%8%2.6×-11.5%+15.8%
GMO Internet 9449.TJapan$1.87B+9%+10%21%14.8×n/an/a

Omnicell bonds and credit

Omnicell has 1 bond outstanding with $172M face value.

Every bond, yield and spread in the cockpit →

Omnicell backlog

Omnicell reported $375M of remaining performance obligations at 30 Sep 2026, down 1% from a year earlier and flat from the previous quarter. That is 0.3 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.

Questions

Who are Omnicell's main competitors?
Named competitors: BD (Pyxis) (BDX), Swisslog Healthcare (private or unlisted), ScriptPro (private or unlisted), Parata Systems (private or unlisted). The cockpit's measured peer set (industry) also includes CETC Cyberspace Security Technology (002268.SZ), Kainos (KNOS.L), ESDS Software Solution (ESDS.NS), Zen Technologies (ZENTEC.NS), Black Box (BBOX.NS), Northking Information Technology (002987.SZ).
Is Omnicell expensive compared with its peers?
On forward p/e it trades at 18.5× against a peer median of 23.2×, 5th cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Omnicell stock performed?
Over six months to 18 Nov 2026 the shares returned -22.5% against -6.9% for the median peer; over one year +1.4%.
What is Omnicell's backlog?
Omnicell's remaining performance obligations (contracted revenue not yet recognised) were $375M at 30 Sep 2026, -1% on a year earlier.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.